share_log

微創機器人-B：自願性公告

MEDBOT-B: VOLUNTARY ANNOUNCEMENT

香港交易所 ·  Mar 5 09:17
Summary by Moomoo AI
上海微創醫療機器人（集團）股份有限公司（「微創機器人」）於2024年3月5日發布自願性公告，預告其2023年全年收入將同比增長超過350%。這一顯著增長主要得益於其旗下產品，包括圖邁四臂腔鏡手術機器人、鴻鵠關節置換手術機器人和蜻蜓眼三維電子腹腔內窺鏡的商業化進程。公司亦預計2023年將錄得不超過人民幣1,050百萬元的淨虧損，較2022年減少，這主要由於營業收入增長和研發效率提升。儘管銷售費用增加和一次性調整開支，公司在國內外市場的商業化進展良好，特別是圖邁多科室註冊自2023年10月獲批後，國內中標進程加速並成功獲得海外訂單。公司表示，將繼續推動產品組合的銷售增長，並提高運營效率。目前，公司正在編製2023年全年業績，預計將於2024年3月31日或之前發布經審核的全年業績公告。
上海微創醫療機器人（集團）股份有限公司（「微創機器人」）於2024年3月5日發布自願性公告，預告其2023年全年收入將同比增長超過350%。這一顯著增長主要得益於其旗下產品，包括圖邁四臂腔鏡手術機器人、鴻鵠關節置換手術機器人和蜻蜓眼三維電子腹腔內窺鏡的商業化進程。公司亦預計2023年將錄得不超過人民幣1,050百萬元的淨虧損，較2022年減少，這主要由於營業收入增長和研發效率提升。儘管銷售費用增加和一次性調整開支，公司在國內外市場的商業化進展良好，特別是圖邁多科室註冊自2023年10月獲批後，國內中標進程加速並成功獲得海外訂單。公司表示，將繼續推動產品組合的銷售增長，並提高運營效率。目前，公司正在編製2023年全年業績，預計將於2024年3月31日或之前發布經審核的全年業績公告。
Shanghai Microchong Medical Robots (Group) Co., Ltd. (“Micro-Chung Robots”) issued a voluntary announcement on March 5, 2024, predicting that its full-year revenue in 2023 will grow by more than 350% year-on-year. This significant growth was driven primarily by the commercialization of its flagship products, including the Tomei quad-arm laparoscopic surgical robot, the Hung Kung joint replacement surgical robot, and the Dragonfly Eye three-dimensional electronic laparoscopy process. The company also expects to record a net loss of no more than RMB1,050 million in 2023, down from 2022, mainly due to increased sales revenue and improved R&D efficiency. Despite the increase in sales expenses and one-time adjustment expenses, the company has made good progress in the commercialization of the domestic and...Show More
Shanghai Microchong Medical Robots (Group) Co., Ltd. (“Micro-Chung Robots”) issued a voluntary announcement on March 5, 2024, predicting that its full-year revenue in 2023 will grow by more than 350% year-on-year. This significant growth was driven primarily by the commercialization of its flagship products, including the Tomei quad-arm laparoscopic surgical robot, the Hung Kung joint replacement surgical robot, and the Dragonfly Eye three-dimensional electronic laparoscopy process. The company also expects to record a net loss of no more than RMB1,050 million in 2023, down from 2022, mainly due to increased sales revenue and improved R&D efficiency. Despite the increase in sales expenses and one-time adjustment expenses, the company has made good progress in the commercialization of the domestic and foreign markets, especially after the registration of the Tomei Doctoral Chamber was approved in October 2023, the process of domestic benchmarking has accelerated and successfully obtained overseas orders. The company said it will continue to drive sales growth in its portfolio and improve operational efficiency. The Company is currently preparing its 2023 Annual Results and is expected to release an audited Annual Results Announcement on or before March 31, 2024.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more